Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Up 546.9% in March

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 951 shares, a growth of 546.9% from the February 26th total of 147 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,385 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 2,385 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the shares of the stock are short sold.

Ascentage Pharma Group International Stock Performance

NASDAQ:AAPG opened at $22.25 on Wednesday. The stock’s fifty day moving average is $24.33 and its 200 day moving average is $30.11. Ascentage Pharma Group International has a fifty-two week low of $17.56 and a fifty-two week high of $48.45. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AAPG. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective on the stock. BTIG Research started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 12th. They set a “buy” rating and a $48.00 target price for the company. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $48.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International in the third quarter worth about $96,000. ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $204,000. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. Finally, Tema Etfs LLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $610,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.